The abstract is read at the publisher; the summary is JClub's.
Engineered 2-N,6-O-sulfated chitosan (26SCS) restores 115% bone mass and prevents 66% bone loss in osteoporosis, surpassing bisphosphonates by targeting RANK Lys97.
- Why it matters: Osteoporosis therapies do not adequately coordinate bone resorption with bone formation, leaving an unmet need for agents that both inhibit osteoclastogenesis and support osteogenesis.
- What they did: The study uses structural/functional analyses to show 26SCS targets K97 in RANK, blocks RANKL signalling to arrest preosteoclast fusion, and enhances PDGF-BB secretion to promote angiogenesis-coupled mineralization.
- The result: By using a carboxyl-free, sequence-controlled dual-sulfation pattern, 26SCS avoids heparin-like competitive binding at K97 and balances osteoclast inhibition with pro-osteogenic effects.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.